Screener / SEC EDGAR /CIK 0001635088 /10-K filed May 20, 2026, compared with May 29, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Roivant Sciences Ltd. ROIV

Compare with peers Embed
The 10-K against last year's

263 changes: 72 added, 30 removed, 151 reworded, 10 quiet changes

10-K May 20, 2026 vs May 29, 2025

10-K 0001635088-26-000061 (May 20, 2026) vs 10-K 0001140361-25-020715 (May 29, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

606 paragraphs · 65 new · 346 reworded · 21 gone · 10-K May 20, 2026 against May 29, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 196 · 50% changed Every version of it
While healthcare professionals are free that direct-to-consumer (“DTC”) advertisements will be subject to use increased scrutiny and prescribe drug products for off-label uses, the FDA strictly regulates manufacturers’ promotion of drug products. In particular, a product may not be promoted for uses that are not approved enforcement by the FDA as reflected in based on its aggressive enforcement posture with respect to DTC prescription drug advertisements. The FDA has also increased its scrutiny of the FDA-approved labeling. A company that data used to substantiate prescription drug and biologic advertising and promotional claims more generally, which may also lead to additional industry enforcement. In the E.U. and the U.K., the promotion of prescription-only medicinal products to any audience, other than licensed healthcare professionals, is found to have improperly promoted off-label uses may be subject to large civil and criminal fines, penalties and enforcement actions. prohibited. If we cannot successfully manage the promotion of our approved product candidates, we could become subject to significant liability, which could materially adversely affect our business and financial condition.
Paragraph 344 · 50% changed Every version of it
Tyvaso •Tyvaso (treprostinil) and Yutrepia (treprostinil), a prostacyclin mimetic, a mimetics, potential competitor competitors to mosliciguat.
Paragraph 572 · 50% changed Every version of it
sales Sales of a substantial amounts number of our common shares by directors, executive officers us or significant shareholders certain of our existing large shareholders, or the perception that such these sales could occur; and occur, could substantially decrease the market price of our common shares. Shares held by
Paragraph 372 · 49% changed Every version of it
Cyber-attacks, Cyberattacks, breaches, interruptions or other data security incidents could result in legal claims or proceedings by private parties or governmental authorities, liability under federal or state laws that protect the privacy of personal information, regulatory penalties, significant remediation costs, disruption of key business operations and diversion of the attention of management and key information technology resources. In the United States, notice of breaches generally must be made to affected individuals, individuals and regulatory authorities in the HHS, states where those individuals reside, and, in certain cases, also to HHS and for extensive breaches, notice may need to be made to the public at large or U.S. state attorneys general. media. Such a notice notices could harm our reputation and our ability to compete. compete, and as demonstrated by other companies’ experience, could trigger large class action lawsuits. In addition, U.S. state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. There can be no assurance that we, We are also subject to SEC rules requiring the disclosure of material cybersecurity incidents within four business days of a materiality determination, as well as annual disclosure of our collaborators, CROs, contractors, consultants cybersecurity risk management processes, strategy and any other business counterparties will be successful in efforts governance. These rules require us to detect, prevent, protect against or fully recover make judgments about the materiality of cybersecurity incidents, and an incorrect determination could itself expose us to securities law liability. Compliance with these disclosure obligations imposes additional operational and legal burdens on our management and may require us to publicly disclose sensitive information about our systems or data from all break-downs, service interruptions, attacks or security breaches or incidents. Although we maintain insurance protection against cybersecurity events or incidents, the costs related to significant security breaches, incidents or disruptions could be material and exceed the limits of any insurance coverage we have, and may result in increases in our insurance costs, or we may otherwise have to expend significant resources to mitigate the impact of such incidents and to develop and implement protections to prevent future events of this nature from occurring. Relevant insurance may in the future become unavailable to us on commercially reasonable terms or at all. Any disruption or security breach or incident that results in or a time when full information is perceived to have resulted in a loss of, or damage to, our data or systems, or inappropriate disclosure, use, acquisition, transfer, modification, unavailability or other processing of confidential or proprietary information, including data related to our personnel, could result in the loss, unauthorized modification, use, unavailability, disclosure or other unauthorized processing of critical or sensitive data, and could cause us to incur liability. Further, in any such event, the development and commercialization of our product candidates following regulatory approval could be delayed and our business and operations could be adversely affected. Any of the foregoing could result in significant financial, legal or reputational harm to us and our business. not yet available.
Paragraph 397 · 49% changed Every version of it
In addition, regulation of AI is rapidly evolving worldwide as legislators and regulators are increasingly focused on these powerful emerging technologies. The technologies underlying AI and its uses are subject to a variety of laws, including intellectual property, privacy, data protection and cybersecurity, consumer protection, competition and equal opportunity laws, and are expected to be subject to increased regulation and new laws or new applications of existing laws. AI is the subject of ongoing review by various U.S. governmental and regulatory agencies, and various U.S. states and other foreign jurisdictions are applying, or are considering applying, their platform moderation, cybersecurity and data protection laws to AI or are considering general legal frameworks for AI. For example, in August 2024, the E.U. Artificial Intelligence Act (the “E.U. AI Act”), which establishes broad obligations for the development and use of AI-based technologies in the E.U. based on their potential risks and level of impact, came into force. The E.U. AI Act includes requirements around transparency, conformity assessments and monitoring, risk assessments, human oversight, security, accuracy, general purpose AI and foundation models, and provides for fines of up to the greater of €35 million or 7% of worldwide annual turnover for violations. We may not be able to anticipate how to respond to these rapidly evolving frameworks, and we may need to expend resources to adjust our offerings in certain jurisdictions if the legal frameworks are inconsistent across jurisdictions. Furthermore, because AI technology itself is highly complex and rapidly developing, it is not possible to predict all of the legal, operational or technological risks that may arise relating to the use of AI.
Paragraph 38 · 48% changed Every version of it
Operating the Vants independently, rather than under a centralized, consolidated management team, may result in increased costs at Roivant and the Vants, as certain functions or processes, including sales and marketing, clinical and nonclinical personnel, business development, finance, accounting, human resources and legal functions, are replicated at Roivant and at multiple Vants. There may also be certain start-up costs associated with the establishment of a new Vant or integration of a newly acquired business into a Vant, which are greater under the Vant model than they would be under a centralized model. The use of the Vant model may also entail increased costs for us, including the time and expenses associated with hiring Vant CEOs and management teams, overseeing Vant equity incentive arrangements and managing compliance-related risks, including the internal controls, accounting systems and other policies and procedures necessary for us to operate as a public company. We may also be exposed to increased “key employee” risks, in the event a Vant CEO were to depart, including the loss of other senior Vant personnel, potentially resulting in adverse impacts to commercialization or development work at the Vant. These increased expenses, complexities and other challenges may make using and scaling the Vant model more challenging and costly than it would be for a traditional pharmaceutical company to both operate and expand the number of product candidates under development, which could make us less competitive relative to our peers that operate in that manner or have a material adverse effect on our consolidated business, financial condition, results of operations or prospects. This decentralized model could also make compliance with applicable laws and regulations more challenging to monitor for us and our Vants and may expose us and our Vants to increased costs that could, in turn, harm our consolidated business, financial condition, results of operations or prospects.
Paragraph 251 · 48% changed Every version of it
Coverage Market acceptance and adequate reimbursement may not be available for sales of our product candidates following regulatory approval, approval will depend in part on the extent to which could make it difficult coverage and adequate reimbursement for us to profitably sell our these product candidates. candidates will be available from third-party
Paragraph 306 · 48% changed Every version of it
We do not own or operate, and do not expect to own or operate, facilities for product manufacturing, storage and distribution or testing. Accordingly, we rely on third parties to produce commercial and clinical supplies of our product candidates. Third-party vendors may be difficult to identify for our product process and formulation development and manufacturing due to special capabilities required, and they may not be able to meet our quality standards. In addition, certain of our third-party manufacturers and suppliers may encounter delays in providing their services as a result of supply chain constraints. If any third-party manufacturers or third parties in the supply chain for materials used in the production of our product candidates are adversely impacted by supply chain constraints, our supply chain may be disrupted, limiting our ability to manufacture our product candidates for our preclinical studies, clinical trials, research and development activities and, following regulatory approval, commercialization. Any significant delay in the supply of a product candidate, or the raw material components thereof, or of equipment and devices as necessary, for either commercialization or an ongoing clinical trial, due to the need to replace a third-party manufacturer or otherwise, could considerably delay marketing efforts for the product in question or the completion of clinical trials, product testing and potential regulatory approval of the product candidate in question. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenue from the sale of our product candidates and may require notification to the FDA or other regulatory authorities. Moreover, as a result of projected supply constraints for certain materials used in the production of our product candidates, we have in the past and may in the future reserve manufacturing capacity in advance of receiving required efficacy or safety results from our clinical trials, which may involve committing substantial financial resources to product candidates that may never be approved or achieve commercialization at scale or at all. In addition, legislative, executive and regulatory proposals were recently enacted or are pending to, among other things, prevent drug shortages, improve pandemic preparedness and reduce the dependency of the U.S. on foreign supply chains and manufacturing; this may include the imposition of tariffs on foreign-manufactured products that we procure. procure as well as limitations on our ability to use biotechnology equipment or services produced or provided by select Chinese biotechnology companies in the performance of federal contracts or grants. While we are still assessing these developments, they could impact our selection and utilization of CMOs, vendors and other suppliers and could have a material adverse impact on our business, financial condition and results of operations.

MD&A

117 paragraphs · 7 new · 63 reworded · 9 gone · 10-K May 20, 2026 against May 29, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 38 · 50% changed
(2) For the years year ended March 31, 2026, included terminated program expenses of $1.9 million for namilumab. For the year ended March 31, 2025, 2024 included terminated program expenses of $12.7 million for namilumab and 2023, our research $1.9 million for RVT-2001. For the year ended March 31, 2024, included terminated program expenses of $13.2 million for namilumab and development expenses consisted of the following: $10.1 million for RVT-2001.
Paragraph 40 · 48% changed
The increase of $78.5 $101.1 million in program-specific costs was primarily driven by increases of $91.1 $79.1 million related to the anti-FcRn franchise, reflecting the progression of our programs, and $15.4 franchise (of which $39.0 million related to mosliciguat, which was acquired during contractual costs recognized in connection with the year ended March 31, 2024. These increases were partially offset by a decrease in expense discontinuation of $35.1 batoclimab), $16.3 million related to RVT-3101, which was sold mosliciguat and $15.1 million related to Roche in December 2023. brepocitinib.
Paragraph 51 · 47% changed
Gain on sale of Telavant net assets decreased by $5.2 billion to $110.4 litigation settlement was $770.2 million for the year ended March 31, 2025, compared 2026 and reflects Genevant’s expected portion of the Fixed Payment to $5.3 billion for be made by Moderna to Genevant and Arbutus as a result of the year ended Settlement Agreement entered in March 31, 2024. 2026. The gain for the year ended March 31, 2025 resulted from the achievement allocation of a one-time milestone in June 2024. The gain for the year ended March 31, 2024 resulted from the sale this Fixed Payment is subject to adjustment upon final determination of our entire equity interest in Telavant to Roche in December 2023. actual litigation costs and expenses incurred. Refer to Note 5, “Recent Transactions and Developments” of our audited financial statements for further information.
Paragraph 45 · 44% changed
There were no acquired Years Ended March 31, Change 2026 2025 2024 2026 vs. 2025 2025 vs. 2024 (in thousands) Acquired in-process research and development expenses for the year ended March 31, 2025. $ $ $26,450 $ $ (26,450)
Paragraph 58 · 40% changed
Gain on sale of Telavant net assets decreased Income tax expense increased by $5.2 billion $85.2 million to $110.4 $133.3 million for the year ended March 31, 2025, 2026, compared to $5.3 billion $48.2 million for the year ended March 31, 2024. 2025. The increase was primarily due to income associated with the gain for the year ended March 31, 2025 resulted from the achievement of a one-time milestone in June 2024. The gain for the year ended March 31, 2024 resulted from the sale of our entire equity interest in Telavant to Roche in December 2023. on litigation settlement. Refer to Note 5, “Recent Transactions and Developments” of our audited financial statements for further additional information.
Paragraph 71 · 36% changed
Our board of directors has authorized a common various share repurchase program, allowing for repurchases of common shares in an aggregate amount of up to programs, including a $1.5 billion (excluding fees and expenses) program that was completed in June 2025 and a subsequent program authorized in June 2025 and subsequently increased in March 2026, allowing for aggregate repurchases up to $1.0 billion (excluding fees and expenses). The repurchase program is funded by As of March 31, 2026, approximately $890.3 million remains available cash and cash equivalents on hand and does not have an expiration date. In April 2024, pursuant to for share repurchases. During the share repurchase program, year ended March 31, 2026, we entered into a share repurchase agreement with Sumitomo and repurchased all 71,251,083 24,225,812 shares (including 270,000 common shares held by Sumitomo at with a purchase price per share trade date of $9.10, March 31, 2025 that settled on April 1, 2025) for an aggregate purchase price of approximately $648.4 million. Subsequent to the repurchase of the common shares held by Sumitomo, additional repurchases of 57,110,703 shares were made in open market transactions under the share repurchase program during $318.1 million (including fees and expenses). During the year ended March 31, 2025 2025, we repurchased 128,361,786 shares for an aggregate purchase price of approximately $644.8 million and together with the Sumitomo repurchase, approximately $1.3 billion of the $1.5 billion approved by our board of directors. (including fees and expenses), including 71,251,083 shares repurchased from Sumitomo Pharma Co., Ltd. at $9.10 per share for approximately $648.4 million.
Paragraph 54 · 36% changed
Change in fair value of liability instruments was a loss of $47.7 million, a gain of $15.8 million, million and a loss of $46.8 million, and a loss of $18.4 million for the years ended March 31, 2025, 2024 2026, 2025 and 2023, 2024, respectively. Change The change in fair value of liability instruments for the year ended March 31, 2025 primarily 2026 consisted of a gain loss relating to the earn-out share liabilities Earn-Out Shares issued as part of the Business Combination. Change The Earn-Out Shares vested during the year ended March 31, 2026. Accordingly, the Earn-Out Shares were remeasured upon their vesting, and these final remeasurements were recognized in the change in fair value of liability instruments for the years ended March 31, 2024 and 2023 primarily consisted of losses relating instruments. No further liability remains related to the warrant and earn-out share liabilities issued as part of the Business Combination. Refer to Note 13, “Earn-Out Shares, Public Warrants and Private Placement Warrants” of our audited financial statements for further information. Earn-Out shares.
Paragraph 103 · 33% changed
For the year ended March 31, 2024, 2026, cash flow from investing financing activities changed by $5.2 approximately $1.4 billion to net cash provided by investing financing activities of $5.2 billion from net cash used in investing activities of $44.3 $134.2 million for the year ended March 31, 2023. 2026 compared to net cash used in financing activities of $1.2 billion for the year ended March 31, 2025. This change in cash flow from investing activities is was primarily due to a decrease in cash used for the repurchase of our common shares, an increase in cash proceeds received upon closing from exercise of stock options and an increase in cash proceeds from the Roche Transaction issuance of subsidiary common shares, net of issuance costs paid, during the year ended March 31, 2024. 2026.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors397 words changed in this paragraph; it is 37% similar to last year's version.
Cyber-attacks, Cyberattacks, breaches, interruptions or other data security incidents could result in legal claims or proceedings by private parties or governmental authorities, liability under federal or state laws that protect the privacy of personal information, regulatory penalties, significant remediation costs, disruption of key business operations and diversion of the attention of management and key information technology resources. In the United States, notice of breaches generally must be made to affected individuals, individuals and regulatory authorities in the HHS, states where those individuals reside, and, in certain cases, also to HHS and for extensive breaches, notice may need to be made to the public at large or U.S. state attorneys general. media. Such a notice notices could harm our reputation and our ability to compete. compete, and as demonstrated by other companies’ experience, could trigger large class action lawsuits. In addition, U.S. state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. There can be no assurance that we, We are also subject to SEC rules requiring the disclosure of material cybersecurity incidents within four business days of a materiality determination, as well as annual disclosure of our collaborators, CROs, contractors, consultants cybersecurity risk management processes, strategy and any other business counterparties will be successful in efforts governance. These rules require us to detect, prevent, protect against or fully recover make judgments about the materiality of cybersecurity incidents, and an incorrect determination could itself expose us to securities law liability. Compliance with these disclosure obligations imposes additional operational and legal burdens on our management and may require us to publicly disclose sensitive information about our systems or data from all break-downs, service interruptions, attacks or security breaches or incidents. Although we maintain insurance protection against cybersecurity events or incidents, the costs related to significant security breaches, incidents or disruptions could be material and exceed the limits of any insurance coverage we have, and may result in increases in our insurance costs, or we may otherwise have to expend significant resources to mitigate the impact of such incidents and to develop and implement protections to prevent future events of this nature from occurring. Relevant insurance may in the future become unavailable to us on commercially reasonable terms or at all. Any disruption or security breach or incident that results in or a time when full information is perceived to have resulted in a loss of, or damage to, our data or systems, or inappropriate disclosure, use, acquisition, transfer, modification, unavailability or other processing of confidential or proprietary information, including data related to our personnel, could result in the loss, unauthorized modification, use, unavailability, disclosure or other unauthorized processing of critical or sensitive data, and could cause us to incur liability. Further, in any such event, the development and commercialization of our product candidates following regulatory approval could be delayed and our business and operations could be adversely affected. Any of the foregoing could result in significant financial, legal or reputational harm to us and our business. not yet available.

Source: Item 1A, 10-K 0001635088-26-000061 vs Item 1A, 10-K 0001140361-25-020715

MD&A211 words changed in this paragraph; it is 30% similar to last year's version.
Our board of directors has authorized a common various share repurchase program, allowing for repurchases of common shares in an aggregate amount of up to programs, including a $1.5 billion (excluding fees and expenses) program that was completed in June 2025 and a subsequent program authorized in June 2025 and subsequently increased in March 2026, allowing for aggregate repurchases up to $1.0 billion (excluding fees and expenses). The repurchase program is funded by As of March 31, 2026, approximately $890.3 million remains available cash and cash equivalents on hand and does not have an expiration date. In April 2024, pursuant to for share repurchases. During the share repurchase program, year ended March 31, 2026, we entered into a share repurchase agreement with Sumitomo and repurchased all 71,251,083 24,225,812 shares (including 270,000 common shares held by Sumitomo at with a purchase price per share trade date of $9.10, March 31, 2025 that settled on April 1, 2025) for an aggregate purchase price of approximately $648.4 million. Subsequent to the repurchase of the common shares held by Sumitomo, additional repurchases of 57,110,703 shares were made in open market transactions under the share repurchase program during $318.1 million (including fees and expenses). During the year ended March 31, 2025 2025, we repurchased 128,361,786 shares for an aggregate purchase price of approximately $644.8 million and together with the Sumitomo repurchase, approximately $1.3 billion of the $1.5 billion approved by our board of directors. (including fees and expenses), including 71,251,083 shares repurchased from Sumitomo Pharma Co., Ltd. at $9.10 per share for approximately $648.4 million.

Source: Item 7, 10-K 0001635088-26-000061 vs Item 7, 10-K 0001140361-25-020715

Accounting Policies150 words changed in this paragraph; it is 47% similar to last year's version.
The Company considers all highly liquid investments in securities with original maturities of greater than three months at the time of purchase to be marketable securities. Marketable securities consist securities, including those that have maturity dates beyond one year from the balance sheet date, are included in current assets on the consolidated balance sheets due to their availability for use in current operations. As of March 31, 2026, marketable securities, consisting of amounts invested in United States (“U.S.”) Treasury securities. securities and corporate bonds, are classified as available-for-sale and carried at fair value. Unrealized holding gains and losses, net of income taxes, on available-for-sale debt securities are reported as a separate component of accumulated other comprehensive (loss) income in stockholders’ equity until realized. The cost of available-for-sale securities sold and the amount reclassified out of accumulated other comprehensive (loss) income into earnings is determined using the specific identification method. As of March 31, 2025, all of the Company’s marketable securities had maturities less than one year from the date of purchase. All of the Company’s marketable securities are were classified as held-to-maturity as the Company has the ability and intent to hold to maturity and are reported carried at amortized cost. Interest income is recorded as earned within “Interest income” in the consolidated statements of operations.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001635088-26-000061 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001140361-25-020715

Legal Proceedings15 words changed in this paragraph; it is 71% similar to last year's version.
Brepocitinib (Priovant Therapeutics, Inc.): •Brepocitinib (Priovant): mid tens-of-millions sales milestone payment to Pfizer if aggregate net sales in a given year exceed a mid-hundreds-of-millions amount. amount and tiered sub-teens royalty on net sales.

Source: Item 3, via Note 12 – Commitments and Contingencies, 10-K 0001635088-26-000061 vs Item 3, via Note 12 – Commitments and Contingencies, 10-K 0001140361-25-020715

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of ROIV's Risk Factors and MD&A, 10-K May 20, 2026 against 10-K May 29, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
such events were to happen, the trading shares of our common shares could decline, and you could lose all or part of your investment. Unless the context otherwise requires, references in this section to “we,” “us,” “our,” “Roivant” and the “Company” refer to Roivant Sciences Ltd. and its subsidiaries and affiliates. References to our “product candidates” include our current product candidates and any future products or product candidates. Approval from the U.S. Food and Drug Administration (“FDA”) or other applicable international regulatory authority is required before a product or product candidate may be marketed and sold in the relevant jurisdiction.
Read it in 10-K May 20, 2026 at sec.gov
AddedRisk Factors
We also face significant competition for investment opportunities. A number of companies compete with us for such opportunities. These companies may possess greater financial or technical resources than we do. If we are unable to
Read it in 10-K May 20, 2026 at sec.gov
AddedRisk Factors
Immunovant relies on the HanAll Agreement to provide the rights to the core intellectual property relating to IMVT-1402 and batoclimab. Any termination or loss of significant rights under the HanAll Agreement could adversely affect Immunovant’s development or commercialization of IMVT-1402.
Read it in 10-K May 20, 2026 at sec.gov
AddedRisk Factors
Our subsidiary Immunovant holds the intellectual property rights to IMVT-1402 and batoclimab under a license agreement with HanAll Biopharma Co., Ltd. (“HanAll”) (the “HanAll Agreement”). The HanAll Agreement imposes a variety of obligations on Immunovant, including those relating to exclusivity, territorial rights, development, commercialization, funding, payment, diligence, sublicensing, insurance, intellectual property protection and other matters. If Immunovant materially breaches any of its obligations under the HanAll Agreement and is unable to cure that breach within the time frame specified under the HanAll Agreement, Immunovant may be required to pay damages to HanAll and HanAll may have the right to terminate the HanAll Agreement, which would result in Immunovant being unable to develop or manufacture its product candidates. Immunovant has commenced discussions with HanAll regarding the potential return to HanAll of certain rights for batoclimab.
Read it in 10-K May 20, 2026 at sec.gov
AddedRisk Factors
Immunovant shared top-line results from the two batoclimab Phase 3 TED studies concurrently in April 2026. Neither study achieved its primary endpoint, leading Immunovant to make a decision to discontinue further development of batoclimab across all indications to focus fully on IMVT-1402. HanAll has a variety of interests in the licensed products under the HanAll Agreement and outside of Immunovant’s licensed territories and may, as a result of those interests,
Read it in 10-K May 20, 2026 at sec.gov
AddedRisk Factors
disagree with, or initiate a dispute with respect to, Immunovant’s plans for batoclimab. While the HanAll Agreement gives Immunovant final decision-making authority over development and regulatory matters for licensed products in Immunovant's licensed territories, and Immunovant believes it has satisfied its obligations under the HanAll Agreement, including with respect to batoclimab, HanAll may disagree with Immunovant's interpretation of the agreement or Immunovant's actions thereunder, and Immunovant may be unable to reach an agreement with HanAll regarding the future of batoclimab. This could result in a dispute with HanAll involving arbitration or litigation. In the event that HanAll asserts a breach, we and Immunovant do not believe there would be any basis for such a claim, and would vigorously contest such a claim if made. Any potential dispute with HanAll could be very expensive and time-consuming, may divert management’s attention from core business functions and may result in unfavorable results that could materially impact Immunovant’s business. In addition, discontinuing further development of and regulatory submissions for batoclimab could impact and result in disputes with third parties, such as with respect to the contract manufacturing of batoclimab, which may be time consuming and expensive to resolve.
Read it in 10-K May 20, 2026 at sec.gov
Show the other 66
AddedRisk Factors
Recent governmental actions and proposals relating to tariffs and other trade policies have created uncertainty about future trading arrangements and the possibility of jurisdictions imposing or increasing tariffs on certain goods. For example, certain governments (including the U.S. and other countries where we do business) have imposed or may impose tariffs on a wide range of products, raw materials and intermediate goods. The U.S. Supreme Court has invalidated some of the U.S. tariffs, but additional tariffs are anticipated to be imposed pursuant to the Trump Administration's ongoing U.S. trade investigation. Additional tariffs, or retaliatory measures by other countries in response, may be implemented at any time. Should these or similar tariffs remain in place (or be re-imposed or increased), or if additional tariffs or trade restrictions are enacted in the future, they could cause us or our future customers to face higher supply costs, delays or require us to switch suppliers. These actions could adversely affect our future margins, profitability, financial condition and results of operations.
Read it in 10-K May 20, 2026 at sec.gov
AddedRisk Factors
In addition, the pharmaceutical industry faces specific and evolving tariff-related risks. On April 2, 2026, the United States announced significant tariffs on certain pharmaceutical products, active pharmaceutical ingredients and key starting materials. These tariffs, which were imposed pursuant to a national security investigation under Section 232 of the Trade Expansion Act of 1962, will generally go into effect in September 2026. The tariffs, which range from 10% to 100% depending on type of product and country of origin, are also subject to a number of exemptions and exclusions. There is still significant uncertainty about implementation and application of the tariffs and the exemptions and exclusions as various elements of the tariff action remain to be determined in subsequent agency actions. These new U.S. tariffs may raise costs for drug products and inputs used in our clinical development programs or that our contract manufacturers and suppliers may procure in connection with manufacturing our product candidates.
Read it in 10-K May 20, 2026 at sec.gov
AddedRisk Factors
We cannot predict future changes in trade policy or the terms of any renegotiated trade agreements, nor can we determine the impact they may have on our business. Any such changes could have a material adverse effect on our business, financial condition and results of operations.
Read it in 10-K May 20, 2026 at sec.gov
AddedRisk Factors
negative impact on our commercial sales. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which economic climate and financial market conditions could adversely impact our business.
Read it in 10-K May 20, 2026 at sec.gov
RemovedRisk Factors
clinicians’ and patients’ perceptions as to the potential advantages and side effects of the product candidate being studied in relation to other available therapies and product candidates;
Read it in 10-K May 29, 2025 at sec.gov
RemovedRisk Factors
A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed on potentially less efficacious control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as a breakthrough therapy, the FDA may later decide that such product candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.
Read it in 10-K May 29, 2025 at sec.gov
RemovedRisk Factors
Regulatory authorities in some jurisdictions, including the U.S., the U.K. and the European Economic Area (the “EEA”), may designate drugs and biologics for relatively small patient populations as orphan drugs. In the U.S., the FDA may designate a drug or biologic as an orphan drug if it is intended to treat a rare disease or condition, which is defined as a disease or condition that affects fewer than 200,000 individuals annually in the U.S. or for which there is no reasonable expectation that costs of research and development of the drug for the disease or condition can be recovered by sales of the drug in the U.S. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug or biologic for the same orphan indication for that time period. In the U.S., in order for a product to receive orphan drug exclusivity, FDA must not have previously approved a drug considered the same drug for the same orphan indication, or the subsequent drug must be shown to be clinically superior to such a previously approved same drug. The applicable period of marketing exclusivity is seven years in the U.S. A similar market exclusivity scheme exists in the EEA. The European Commission, on the basis of a scientific opinion by the EMA’s Committee for Orphan Medicinal Products grants Orphan Drug Designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the E.U. Additionally, designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the E.U. would be sufficient to justify the necessary investment in developing the drug or biological product. In any event, Orphan Drug Designation is granted only if there is no satisfactory method of diagnosis, prevention or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. Orphan designation in the E.U. entitles a party to certain benefits, such as scientific assistance (protocol assistance), financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This orphan market exclusivity period prevents the European Commission, EMA and the competent authorities of the E.U. Member States from accepting an application or granting marketing authorization for any similar medicinal product intended for the same orphan indication. The orphan market exclusivity applies in parallel to the “normal” data and market exclusivity in the EEA, whereby no company can make reference to (rely on) the innovator drug company’s preclinical and clinical data in order to obtain a marketing authorization for eight years from the date of the first approval of the innovator drug in the EEA and no generic or biosimilar drug can be marketed for ten years from the first approval of the innovator drug in the EEA; the innovator drug may qualify for an extra year’s protection. This additional one year of marketing exclusivity may be obtained where the innovator company is granted, during the first eight years of the ten years market exclusivity, a marketing authorization for a significant new indication for the relevant medicinal product. In such a situation, the generic or biosimilar company can only market their product after 11 years from the first grant of the innovator company’s marketing authorization for the product in the EEA.
Read it in 10-K May 29, 2025 at sec.gov
RemovedRisk Factors
In June 2016, the electorate in the United Kingdom voted in favor of leaving the European Union (commonly referred to as Brexit). Thereafter, in March 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The United Kingdom formally left the European Union in January 2020. A transition period began in February 2020, during which E.U. pharmaceutical law remained applicable in the United Kingdom. However, this ended in December 2020. In December 2020, the United Kingdom and European Union signed the Trade and Cooperation Agreement which includes an agreement on free trade between the two parties, although provides minimal provisions on medicinal products. Since that time, Great Britain operated a separate regulatory regime for medicinal products, although Northern Ireland continued to follow EU law. Further, in March 2023, an agreement was reached by the U.K. and EU (the “Windsor Agreement”), relating to post-Brexit trade issues in Northern Ireland, which has applied from January 2025. This seeks to simplify the supply of medicines between Great Britain and Northern Ireland and means EU legislation does not apply in all cases in Northern Ireland. Since the regulatory framework in the United Kingdom covering the quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorizations, commercial sales, and distribution of pharmaceutical products is derived from E.U. Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the United Kingdom, as the U.K. legislation now has the potential to diverge from E.U. legislation. This continues to impact regulatory requirements for medicinal products and devices in the United Kingdom. The MHRA has published detailed guidance for industry and organizations on the position in the United Kingdom, and continues to update this as the United Kingdom’s regulatory position on medicinal products and medical devices evolves. There are also a number of ongoing consultations on the future legislation in the U.K., in particular in relation to the clinical trials and medical devices frameworks in the UK.
Read it in 10-K May 29, 2025 at sec.gov
RemovedRisk Factors
We also face competition from solutions that biopharmaceutical companies develop internally and from smaller companies that offer products and services directed at more specific markets than we target, enabling these smaller competitors to focus a greater proportion of their efforts and resources on these markets, in both healthcare technology and drug discovery.
Read it in 10-K May 29, 2025 at sec.gov
RemovedRisk Factors
In February 2022, Roivant’s subsidiary GSG and its affiliate Arbutus filed a lawsuit in the U.S. District Court for the District of Delaware against Moderna and an affiliate seeking damages for infringement of U.S. Patent Nos. 8,058,069, 8,492,359, 8,822,668, 9,364,435, 9,504,651, and 11,141,378 in the manufacture and sale of MRNA-1273, Moderna’s vaccine for COVID-19 (the “Moderna Action”). In November 2022, the District Court denied Moderna’s partial motion to dismiss pursuant to 28 U.S.C. § 1498(a) (“§ 1498”). In March 2023, following the submission of a Statement of Interest in the case by the U.S. Government, the court reaffirmed its prior decision and again ruled that the complaint should not be partially dismissed on the basis of § 1498. In February 2024, the court held a claim construction hearing on disputed terms within the claims of the asserted patents. On April 3, 2024, the court provided its claim construction ruling, in which it construed the disputed claim terms and agreed with GSG and Arbutus’ position on most of the disputed claim terms. Fact discovery in the Moderna Action has been completed, and expert discovery is on-going. The court in the Moderna Action has informed the parties that it plans to update the timing for the summary judgment phase and jury trial, previously scheduled for the second or third quarter of calendar year 2025 and September 2025, respectively.
Read it in 10-K May 29, 2025 at sec.gov
RemovedRisk Factors
In addition, in March 2025, GSG and Arbutus filed five international lawsuits against Moderna targeting alleged infringing activity in 30 countries (the “International Cases”). These cases are:
Read it in 10-K May 29, 2025 at sec.gov
RemovedRisk Factors
Canada: Federal Court of Canada File No. T-704-25, seeking a permanent injunction and damages or, if GSG so elects, an accounting of Moderna’s profits, attributable to infringement of Canadian Patent No. 2,721,333.
Read it in 10-K May 29, 2025 at sec.gov
RewordedRisk Factors
Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other regulatory the competent authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a clinical benefit from using a product candidate, changes in governmental regulations or administrative actions, developments on trials conducted by us or our competitors for related technology that raises regulatory concerns about risk to patients of the technology broadly, or lack of adequate funding to continue the clinical trial. E.U.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct Member States and the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA U.K. or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a clinical benefit from using a product candidate, changes in governmental regulations or administrative actions, developments on trials conducted by us or our competitors for related technology that raises regulatory concerns about risk to patients of the technology broadly, or lack of adequate funding to continue the clinical trial.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
As previously disclosed, our board of directors has authorized a repurchases of our common shares in an aggregate amount of up to $1.0 billion (excluding fees and expenses) (in addition to the previously disclosed common share repurchase program, program allowing for repurchases repurchase of our common shares in an aggregate amount of up to $1.5 billion (excluding fees and expenses) (the “2024 Repurchase Program”). expenses), which was fully exhausted as of June 30, 2025).
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
The resolution of any dispute or disagreement involving contract interpretation disagreement that may arise in relation to the HanAll Agreement could affect the scope of our Immunovant's rights to the relevant intellectual property or technology, its product candidates or affect financial or other obligations under the relevant agreement, HanAll Agreement or other agreements related to the development and commercialization of Immunovant's product candidates, either of which could harm our business, financial condition, results of operations and prospects.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
In addition, the proposal envisages legislation changes to the concept of unmet medical need and considers introducing novel additional rewards for orphan medicinal products considered to be “breakthrough orphan medicinal products” (i.e., orphan medicinal products addressing a high unmet medical need. disease with no current available medicinal treatment and which bring a clinically relevant reduction in morbidity or mortality).
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
Our Further, our computational drug discovery Vants, including VantAI, which uses machine learning to build computational models to generate new molecular entities for targets of interest, and Psivant, which uses molecular dynamics to design small molecules for highly validated hard-to-drug targets, efforts face competition from both established industry competitors and an increasing wave of competition in the in silico discovery and development worlds, including startups, large and mid-sized biopharmaceutical companies, large technology companies and others.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
Following the Dermavant Transaction we We do not currently have any product candidates that have received marketing approval anywhere in the world commercial stage products and we do not expect to generate product revenues from the commercial sale of our product candidates in the near term. until we receive applicable regulatory approvals for one of our product candidates.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
AI can present ethical issues and may subject us to new or heightened legal, regulatory, ethical or other challenges; and inappropriate or controversial data practices by developers and end-users, or other factors adversely affecting public opinion of AI, could impair the acceptance of AI solutions, including those incorporated in our businesses. challenges.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
U.S. holders that own 10% or more of the combined voting power or value of our common shares may suffer adverse tax consequences because we and be subject to U.S. federal income taxation on our non-U.S. subsidiaries may be characterized as “controlled foreign corporations” (“CFCs”) under Section 957(a) of the Code. undistributed earnings.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
These increased expenses, complexities and other challenges may make using and scaling the Vant model more challenging and costly than it would be for a traditional pharmaceutical company to both operate and expand the number of product candidates under development, which could have a material adverse effect on our consolidated business, financial condition, results of operations or prospects.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
In addition, legislative, executive and regulatory proposals were recently enacted or are pending to, among other things, prevent drug shortages, improve pandemic preparedness and reduce the dependency of the U.S. on foreign supply chains and manufacturing; this may include the imposition of tariffs on foreign-manufactured products that we procure. procure as well as limitations on our ability to use biotechnology equipment or services produced or provided by select Chinese biotechnology companies in the performance of federal contracts or grants.
Read it in 10-K May 20, 2026 at sec.gov
RewordedRisk Factors
“Global intangible low-taxed income” GILTI may include most of the remainder of a CFC’s income over a deemed return on its tangible assets, and “net CFC tested income” generally is similar to GILTI, but is computed without accounting for any such deemed return on a CFC’s tangible assets.
Read it in 10-K May 20, 2026 at sec.gov
Quiet changesRisk Factors
The amount of cash available to return to shareholders, if any, can may vary significantly from period to period for a number of reasons, including, among other things, our results of operations, financial condition, cash requirements, contractual restrictions, applicable law and other factors that our board of directors may deem relevant.
Read it in 10-K May 20, 2026 at sec.gov
Quiet changesRisk Factors
Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, substantially increase the costs of commercializing our any product candidates in the future following regulatory approval, and could significantly harm our business, financial condition, results of operations and growth prospects.
Read it in 10-K May 20, 2026 at sec.gov
Quiet changesRisk Factors
The healthcare budgetary constraints in most countries have resulted in restrictions on the pricing and reimbursement of medicines, and generally a similar approach is taken in the U.K. where a key consideration is the affordability of drugs for treatment of patients under the National Health Service.
Read it in 10-K May 20, 2026 at sec.gov
Quiet changesRisk Factors
In that case, we anticipate that our corporate structure and intercompany transactions, including the manner in which we develop and use our intellectual property, will be organized so that we can achieve our business objectives in a tax-efficient manner and in compliance with applicable transfer pricing rules and regulations.
Read it in 10-K May 20, 2026 at sec.gov
Quiet changesRisk Factors
If taxing authorities were to allocate income to a higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would could increase its our consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows.
Read it in 10-K May 20, 2026 at sec.gov
Quiet changesRisk Factors
As we intend to operate in numerous countries and taxing jurisdictions, the application of tax laws can be subject to diverging and sometimes conflicting interpretations by tax authorities of these jurisdictions.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
Gain on litigation settlement reflects a gain resulting from the settlement agreement (the “Settlement Agreement”) entered between our subsidiary, Genevant Sciences GmbH (“Genevant”), Arbutus Biopharma Corporation (together with Genevant, “Genevant/Arbutus”), and, solely for certain purposes, Genevant’s parent Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) in March 2026 to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Genevant/Arbutus’ lipid nanoparticle (“LNP”) delivery technology in its vaccines, including SPIKEVAX. We recognized a gain on litigation settlement of $770.2 million during the year ended March 31, 2026 in the accompanying consolidated statements of operations for Genevant’s expected portion of the $950 million non-contingent, non-creditable, and non-refundable payment to be made by Moderna to Genevant and Arbutus on or before July 8, 2026 (the “Fixed Payment”). The allocation of this Fixed Payment is subject to adjustment upon final determination of actual litigation costs and expenses incurred. Refer to Note 5, “Recent Transactions and Developments” of our audited financial statements for further information regarding the Settlement Agreement.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
The increase of $21.6 million in personnel-related expenses, which is an unallocated internal cost, was primarily driven by higher headcount to support additional clinical studies for the anti-FcRn franchise activities at Immunovant and brepocitinib at Priovant. The $8.1 million increase in share-based compensation expense was primarily driven by the Priovant Exchange Offer. Refer to Note 9, “Share-Based Compensation and Other Compensation Plans” of our financial statements for further details.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
Our short-term and long-term liquidity requirements as of March 31, 2026 included obligations under our leases (see Note 11, “Leases” of our audited financial statements). As of March 31, 2026, our subsidiary, Immunovant, had an accumulated accrual of $42.5 million of non-cancelable contractual costs as a result of the discontinuation of batoclimab, of which $39.0 million was recognized as research and development expense during the year ended March 31, 2026. Beyond this, we do not currently have any other material contractually obligated minimum purchases or firm non-cancelable purchase commitments. We anticipate other purchases in the ordinary course of business and have other payment obligations as discussed below.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
For the year ended March 31, 2026, cash used in operating activities decreased by $89.1 million to $750.3 million compared to $839.5 million for the year ended March 31, 2025. This decrease was primarily due to certain cost savings during the year ended March 31, 2026 as a result of the sale of Dermavant along with lower cash compensation during the year ended March 31, 2026 as a result of higher one-time cash awards made pursuant to the Senior Executive Compensation Program during the year ended March 31, 2025. These decreases were partially offset by lower cash receipts from revenues in part as a result of the sale of Dermavant, less interest income received and greater cash requirements to advance our existing research and development programs, including the anti-FcRn franchise and brepocitinib, during the year ended March 31, 2026.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Updates (“ASU”) 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which requires updates to the income tax disclosures related to the rate reconciliation and disaggregation of income taxes paid by jurisdiction. The amendments are effective for fiscal years beginning after December 15, 2024 and are applicable to our fiscal year beginning April 1, 2025, with early adoption permitted. The amendments should be applied prospectively, however retrospective application is permitted. We adopted this ASU prospectively for the fiscal year ended March 31, 2026. This resulted in expanded disclosures in line with the requirements of the ASU.
Read it in 10-K May 20, 2026 at sec.gov
AddedMD&A
In September 2025, the FASB issued ASU 2025-07, “Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract”, which refines the scope of the guidance on derivatives in ASC 815 and clarifies the guidance on share-based payments from a customer in ASC 606. This guidance is effective for fiscal years and interim periods beginning after December 15, 2026, with early adoption permitted. These requirements may be applied prospectively or on a modified retrospective basis through a cumulative-effect adjustment to the opening balance of retained earnings. We early adopted this guidance during the quarter ended March 31, 2026. We applied the derivative scope refinements guidance on a modified retrospective basis and applied the share-based payments guidance on a prospective basis. The adoption of this guidance had no impact on our consolidated financial statements.
Read it in 10-K May 20, 2026 at sec.gov
RemovedMD&A
For the year ended March 31, 2023, loss from discontinued operations, net of tax also includes the gain on sale of common shares of Myovant Sciences Ltd. (“Myovant”) as a result of Sumitovant Biopharma Ltd.’s (“Sumitovant”) acquisition of the remaining noncontrolling interest in Myovant in March 2023. We were entitled to these shares of Myovant pursuant to the December 2019 transaction with Sumitomo Pharma Co., Ltd. (the “Sumitomo Transaction”) that included, among other things, the transfer of our ownership interest in five Vants to Sumitovant. The Sumitomo Transaction was presented as discontinued operations during the year ending March 31, 2020, and the right to receive certain common shares of Myovant was treated as a contingent consideration upon a sale of the business and accounted for as a gain contingency.
Read it in 10-K May 29, 2025 at sec.gov
RemovedMD&A
Gain on deconsolidation of subsidiaries was $3.1 million, $32.8 million, and $29.3 million for the years ended March 31, 2025, 2024 and 2023, respectively. The gain for the year ended March 31, 2025 resulted from the deconsolidation of a subsidiary in March 2025. The gain for the year ended March 31, 2024 resulted from the deconsolidation of certain subsidiaries, including VantAI Holdings, Inc. in July 2023 and Proteovant in August 2023. The gain for the year ended March 31, 2023 resulted from the deconsolidation of certain subsidiaries in November 2022 and July 2022.
Read it in 10-K May 29, 2025 at sec.gov
RemovedMD&A
certain commitments to Samsung Biologics Co., Ltd. (“Samsung”) pursuant to a Product Service Agreement (“PSA”) entered into between Immunovant and Samsung pursuant to which Samsung will manufacture and supply Immunovant with batoclimab drug substance for commercial sale, if approved, and perform other manufacturing-related services with respect to batoclimab. Upon execution of the PSA, Immunovant committed to purchase process performance qualification batches of batoclimab and pre-approval inspection batches of batoclimab which may be used for regulatory submissions and, pending regulatory approval, commercial sale. In addition, Immunovant has a minimum obligation to purchase additional batches of batoclimab in the four-year period of 2026 through 2029. As of March 31, 2025, the remaining minimum purchase commitment related to this agreement was estimated to be approximately $43.6 million, of which $5.5 million, $10.1 million, $14.0 million and $14.0 million is expected to be paid during the fiscal years ending March 31, 2026, 2028, 2029 and 2030, respectively.
Read it in 10-K May 29, 2025 at sec.gov
RemovedMD&A
The above purchase commitments do not represent all of our anticipated purchases, but instead represent only the contractually obligated minimum purchases or firm commitments of non-cancelable minimum amounts.
Read it in 10-K May 29, 2025 at sec.gov
RemovedMD&A
In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” which updates reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024. These amendments should be applied retrospectively to all prior periods presented in the financial statements. Beginning with this Annual Report on Form 10-K, we adopted this standard which resulted in incremental segment disclosures. Refer to Note 16, “Segment Information” for disclosure of the information required under ASU 2023-07.
Read it in 10-K May 29, 2025 at sec.gov
RewordedMD&A
The increase of $78.5 $101.1 million in program-specific costs was primarily driven by increases of $91.1 $79.1 million related to the anti-FcRn franchise, reflecting the progression of our programs, and $15.4 franchise (of which $39.0 million related to mosliciguat, which was acquired during contractual costs recognized in connection with the year ended March 31, 2024. discontinuation of batoclimab), $16.3 million related to mosliciguat and $15.1 million related to brepocitinib.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
For the year ended March 31, 2025, cash flow from investing activities changed by approximately $7.0 billion to net 2026, cash used in investing activities of decreased by approximately $1.1 billion to $682.3 million compared to $1.8 billion for the year ended March 31, 2025 from net cash provided by investing activities of $5.2 billion for the year ended March 31, 2024. 2025.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
For the year ended March 31, 2024, 2026, cash flow from investing financing activities changed by $5.2 approximately $1.4 billion to net cash provided by investing financing activities of $5.2 billion from net cash used in investing activities of $44.3 $134.2 million for the year ended March 31, 2023. 2026 compared to net cash used in financing activities of $1.2 billion for the year ended March 31, 2025.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
Income (loss) from discontinued operations, net of tax was $373.0 million consists of the gain on sale of subsidiary interests for the year ended March 31, 2025 and reflects the gain on sale of subsidiary interests resulting from the sale of our entire equity interest in our majority-owned subsidiary, Dermavant, to Organon in October 2024, partially offset by Dermavant’s net losses. Dermavant Sciences Ltd.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
Research and development expenses increased This increase was primarily driven by $110.5 million to $550.4 million for the year ended March 31, 2025, compared to $439.9 million for the year ended March 31, 2024, primarily due to increases in program-specific costs of $78.5 million, personnel-related expenses of $22.9 million, share-based compensation of $7.4 million and other expenses of $1.7 million.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
Research and development expenses increased by $110.5 million to $550.4 million for the year ended March 31, 2025, compared to $439.9 million for the year ended March 31, 2024, primarily due to increases in program-specific costs of $78.5 million, personnel-related expenses of $22.9 million, share-based compensation of $7.4 million and other expenses of $1.7 million. 2024.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
For the years ended March 31, 2025, 2024 2026, 2025 and 2023, 2024, we had a net loss losses from continuing operations of $397.9 million and $729.8 million, million and had net income from continuing operations of approximately $4.5 billion and a net loss from continuing operations of $889.1 million, billion, respectively.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 currently under review at the FDA for the treatment of dermatomyositis and JAK1 also in late stage development for the treatment of dermatomyositis, non-infectious uveitis uveitis, cutaneous sarcoidosis and cutaneous sarcoidosis; lichen planopilaris;
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
A summary of general and administrative expense relating to the Cash one-time cash retention bonus award to its employees awarded during the year ended March 31, 2024 (the “Cash Bonus Program Program”) and 2024 Senior Executive Compensation Program is as follows (in thousands):
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
Change in fair value of liability instruments was a loss of $47.7 million, a gain of $15.8 million, million and a loss of $46.8 million, and a loss of $18.4 million for the years ended March 31, 2025, 2024 2026, 2025 and 2023, 2024, respectively.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
The change of $27.2 $49.9 million was primarily driven by changes in the public share prices price of our equity investments, including Arbutus, as well as the change in fair value of our investment in Datavant. Datavant, which was driven by growth in forecasted financial performance.
Read it in 10-K May 20, 2026 at sec.gov
RewordedMD&A
In October 2022, December 2025, Immunovant completed an underwritten public offering of 12,500,000 26,200,000 shares of its common stock (including 416,667 16,666,666 shares of common stock purchased by us) at a price to the public of $6.00 $21.00 per share, for net proceeds to Immunovant of approximately $70.2 $543.6 million after deducting underwriting discounts and commissions and offering expenses.
Read it in 10-K May 20, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ROIV/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.